The Indian Drugs Controller General Approves Start of Hemispherx Biopharma's Study Study (HEB)

Hemispherx Biopharma, Inc.

, an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders, and Max Neeman International, one of the leading and largest clinical research organizations ("CROs") in India, jointly announce that the collaborative Phase II clinical research effort for one of Hemispherx' flagship products, Alferon N Injection(R) (interferon Alfa-n3) was approved by the Indian Drugs Controller General on July 13, 2010 and is expected to start enrolling patients right away. The clinical research platform is designed to improve the quality of care for treatment of seriously ill patients hospitalized with either seasonal influenza or pandemic influenza. The CRO targeted clinical sites that will be enrolling subjects in the current monsoon season. According to various expert epidemiological sources, strains of influenza are becoming progressively resistant to currently available commercial antiviral drugs (including so-called neuraminidase inhibitors) and death rates are expected to increase globally without the development of new effective treatment strategies.